Interview with Richard de Souza, CEO, Martindale Pharma
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Address: Hubert Road
Brentwood
Essex CM14 4JY
,United Kingdom
Tel: +44 (0) 1277 266 600
Web: http://www.martindalepharma.co.uk/
After starting out as a London chemist store owned by William Martindale, Martindale Pharma has remained in business for more than a century. The company’s reputation as a leading UK manufacturer and supplier of specialty prescription pharmaceutical products for healthcare professionals, working in both Primary and Secondary Care, has grown steadily over that time. Martindale Pharma is now firmly established as a leading supplier to the UK’s NHS and exports its products to a number of other major pharmaceutical markets. Martindale Pharma has a clearly defined mission: to provide medicines to improve the quality of people’s lives.
Martindale Pharma has built strong relationships with prescribers and influencers on drug choice in its chosen business segments (see below). Working on the basis of a partnership, Martindale Pharma has also built a strong relationship with healthcare service providers such as Alliance Boots, Celesio, AAH, Lloyds, Co-Operative Pharmacies, as well as the NHS. Our operating philosophy is one of close co-operation and responsiveness to customer needs.
Key Business Segments:
Addiction
Martindale Pharma is ranked number one in market share in the opiate addiction market, driven by the success of our brand Physeptone, the UK’s leading methadone product. We work in partnership with the NHS, Community Drug Teams, third party providers of addiction services as well as retail pharmacies to ensure that drug service users receive the optimum support as they seek to move away from the use of illicit opiates.
Critical Care
Martindale Pharma manufacture and market the Aurum Range, the UK’s leading range of 11 pre-filled syringes for emergency use by resuscitation and operating theatre teams. We also manufacture and market a Caffeine product for treatment of Apnoea of Prematurity a critical care area in neonatology.
Specials
Martindale Pharma can manufacture over 30,000 products in a range of formulations. Handling around 700-800 individual orders a day for these highly personalised medicines, the majority of products are made by our dedicated team of pharmacists and technical staff. Over 90% of orders are supplied to the customer within 24 hours of ordering. Martindale Pharma is ranked number one by market share in this segment.
Ophthalmics
Martindale Pharma provides a broad range of ophthalmic products as generic, own label and third party brands. We are one of the top three companies in our chosen Ophthalmics disease segments.
Hospital Speciality Products
Martindale Pharma’s range of principally parenteral products are used in a wide range of hospital situations. We are one of the country’s leading manufacturers of sterile injection products supplying over 25 million ampoules a year.
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing…
A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status…
The Window Conference Center is hosting at least six pharmaceutical events within a month, and has a broad prior history of orchestrating such occasions. How important is the pharmaceutical industry…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
You joined Apodi in 2008, after a hiatus from the industry following the sale of your previous company, In2Focus, in 2007. What has been the most challenging aspect of your…
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
See our Cookie Privacy Policy Here
